Document Type : Case Report

Authors

1 Juronghealth Campus - Ng Teng Fong General Hospital, National University Health System

2 Department of Intensive Care Medicine, Ng Teng Fong General Hospital, National University Health System, Singapore

3 Department of Intensive Care Medicine, Juronghealth Campus, National University Health System, Singapore.

4 Division Director, Analytical Toxicology Division, Applied Science Group, Health Sciences Authority (HSA) Singapore

Abstract

Case Presentation: 
We present a case of Cerbera fruit ingestion which highlight the knowledge gap in unusual glycoside poisoning. Despite the patient’s asymptomatic presentation, life threatening clinical features such as hyperkalaemia, hypotension and arrhythmia occurred later. Treatments instituted were activated charcoal (AC), atropine, hyperkalaemia management, Digoxin Fab and intravenous lipid emulsion (ILE). Advanced Cardiac Life Support (ACLS) was instituted with automated chest compression device. The patient died despite prolonged of resuscitation effort. Cerbera glycoside toxicity warrants serious consideration in view of rare presentation and unpredictable nature of toxicology. 

Discussion: 
We highlight the prevalence of Cerbera species in Asia-Pacific and present the similarities of cardiac glycosides pharmacology. Early recognition of ingestion and cardiac monitoring are particularly important. In this case, we highlight the diagnostic and prognostic challenge as patient deteriorated despite normal serum digoxin level. As the evidence of Cerbera glycoside poisoning treatment options is lacking, we take this opportunity to examine treatment options assuming similar pharmacology among cardiac glycoside family. We argue for a case for use of Digoxin Fab which is the prevailing treatment for glycoside poisoning. Multi-dose-activated charcoal (MDAC) and ILE are postulated to have physiological basis given current evidence. Electrical and pharmacology treatment for arrhythmia were explored as there is limited evidence. We propose ECMO should always be considered for cardiac toxicity in anticipation of treatment failure as the novel therapy has shown great promise. 

Conclusion: 
Cerbera glycoside poisoning should be treated with utmost caution as the fruit is easily accessible and highly toxic. Close cardiac monitoring is a must due to high mortality risk. Digoxin Fab should be instituted as guided by toxicologist. Patients should be transferred to ECMO centre for observation in all cases due to the unpredictable nature of toxin. Further investigation of treatment is awaited.

Keywords

1.Gaillard Y, Krishnamoorthy A, Bevalot F. Cerbera odollam: a “suicide tree” and cause of death in the state of Kerala, India. J Ethnopharmacol. 2004; 95:123–6.
2. Cerbera odollam. Available from: https://lkcnhm.nus.edu.sg/dna/organisms/details/302 Accessed August 11, 2019
3. Flora Fauna Web. [cited 2019 Nov 12]. Available from: https://florafaunaweb.nparks.gov.sg/Special-Pages/plantdetail.aspx?id=2800 Accessed August 11, 2019
4. Menezes RG, Usman MS, Hussain SA, Madadin M, Siddiqi TJ, Fatima H, et al. Cerbera odollam toxicity: A review. J Forensic Leg Med. 2018; 58:113–6.
5. Severson E, Jufer-Phipps R, Fowler DR, Alexander R. Beyond the Boundaries of Forensic Toxicology - the Use of an Atypical Consultant in a Rare Case of Cerberin Poisonin. Academic Forensic Pathology. 2015; 5:140–4.
6. Kassop D, Donovan MS, Cohee BM, Mabe DL, Wedam EF, Atwood JE. An unusual case of cardiac glycoside toxicity. Int J Cardiol. 2014;170: 434–7.
7. Eddleston M, Haggalla S. Fatal injury in eastern Sri Lanka, with special reference to cardenolide self-poisoning with Cerbera manghas fruits. Clin Toxicol. 2008; 46:745–8.
8. Carlier J, Guitton J, Bévalot F, Fanton L, Gaillard Y. The principal toxic glycosidic steroids in Cerbera manghas L. seeds: Identification of cerberin, neriifolin, tanghinin and deacetyltanghinin by UHPLC–HRMS/MS, quantification by UHPLC–PDA-MS. Journal of Chromatography B. 2014; 962:1–8.
9. Cheenpracha S, Karalai C, Rat-A-Pa Y, Ponglimanont C, Chantrapromma K. New cytotoxic cardenolide glycoside from the seeds of Cerbera manghas. Chem Pharm Bull. 2004; 52:1023–5.
10. Prassas I, Diamandis EP. Novel therapeutic applications of cardiac glycosides. Nat Rev Drug Discov. 2008; 11:926–35.
11. Nelson LS, Hoffman RS, Howland MA, Lewin NA, Goldfrank LR. Goldfrank’s Toxicologic Emergencies, Eleventh Edition. McGraw Hill Professional; 2018.
12. Wermuth ME, Vohra R, Bowman N, Furbee RB, Rusyniak DE. Cardiac Toxicity from Intentional Ingestion of Pong-Pong Seeds (Cerbera Odollam). J Emerg Med. 2018; 55:507–11.
13. Menon MS, Kumar P, Jayachandran CI. Clinical Profile and Management of Poisoning with Suicide Tree: An Observational Study. Heart Views. 2016; 17:136–9.
14. Roberts DM, Gallapatthy G, Dunuwille A, Chan BS. Pharmacological treatment of cardiac glycoside poisoning. British Journal of Clinical Pharmacology. 2016; 81:488–95.
15. Khajja BS, Sharma M, Singh R. Forensic Study of Indian Toxicological Plants as Botanical Weapon (BW): A Review. Journal of Environmental & Analytical Toxicology. 2011; 1: 112.
16. Radford DJ, Cheung K, Urech R, Gollogly JR, Duffy P. __________ 127 Immunological detection of cardiac glycosides in plants. Aust Vet J. 1994; 71:236–8.
17. Laphookhieo S, Cheenpracha S, Karalai C, Chantrapromma S, Rat-a-Pa Y, Ponglimanont C, et al. Cytotoxic cardenolide glycoside from the seeds of Cerbera odollam. Phytochemistry. 2004; 65: 507–10.
18. Maillaud C, Lefebvre S, Sebat C, Barguil Y, Cabalion P, Cheze M, et al. Double lethal coconut crab (Birgus latro L.) poisoning. Toxicon. 2010; 55:81–6.
19. Laizure SC, Herring V, Hu Z, Witbrodt K, Parker RB. The role of human carboxylesterases in drug metabolism: have we overlooked their importance? Pharmacotherapy. 2013; 33:210– 22.
20. Renymol B, Palappallil D, Ambili N. Study on clinical profile and predictors of mortality in Cerbera odollam poisoning. Indian J Crit Care Med. 2018; 22:431–4.
21. Bismuth C, Gaultier M, Conso F, Efthymiou ML. Hyperkalemia in Acute Digitalis Poisoning: Prognostic Significance and Therapeutic implications. Clinical Toxicology. 1973; 6: 153–62.
22. Antman EM, Wenger TL, Butler VP Jr, Haber E, Smith TW. Treatment of 150 cases of life-threatening digitalis intoxication with digoxin-specific Fab antibody fragments. Final report of a multicenter study. Circulation. 1990; 81:1744–52.
23. Woolf AD, Wenger T, Smith TW, Lovejoy FH Jr. The Use of Digoxin-Specific Fab Fragments for Severe Digitalis Intoxication in Children. N Engl J Med. 1992; 326:1739–44.
24. Roberts DM, Buckley NA. Antidotes for acute cardenolide (cardiac glycoside) poisoning. Cochrane Database Syst Rev . 2006; 4:CD005490. Available from: http://dx.doi.org/10.1002/14651858.CD005490.pub2. Accessed August 1, 2019.
25. Rajapakse S. Management of yellow oleander poisoning. Clin Toxicol. 2009; 47:206–12.
26. Cheung K, Urech R, Taylor L, Duffy P, Radford D. Plant cardiac glycosides and digoxin Fab antibody. J Paediatr Child Health. 1991; 27:312–3.
27. Roberts DM, Southcott E, Potter JM, Roberts MS, Eddleston M, Buckley NA. Pharmacokinetics of digoxin cross-reacting substances in patients with acute yellow Oleander (Thevetia peruviana) poisoning, including the effect of activated charcoal. Ther Drug Monit. 2006; 28:784–92.
28. Lip GY, Metcalfe MJ, Dunn FG. Diagnosis and treatment of digoxin toxicity. Postgrad Med J. 1993; 69:337–9. Available from: http://pmj.bmj.com/cgi/doi/10.1136/pgmj.69.811.337 Accessed August 15, 2019
29. de Silva HA, Fonseka MMD, Pathmeswaran A. Multiple-dose activated charcoal for treatment of yellow oleander poisoning: a single-blind, randomised, placebo-controlled trial. Lancet. 2003; 361:1935–8.
30. American Academy of Clinical Toxicology, European Association of Poisons Centres and Clinical Toxicologists. Position Statement and Practice Guidelines on the Use of Multi-Dose Activated Charcoal in the Treatment of Acute Poisoning. J Toxicol Clin Toxicol. 1999; 37:731–51.
31. Eddleston M, Juszczak E, Buckley NA, et al. Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet. 2008; 371:579–87.
32. Dasgupta A, Emerson L. Neutralization of cardiac toxins oleandrin, oleandrigenin, bufalin, and cinobufotalin by digibind: Monitoring the effect by measuring free digitoxin concentrations. Life Sciences. 1998; 63:781–8.
33. Bandara V, Weinstein SA, White J, Eddleston M. A review of the natural history, toxinology, diagnosis and clinical management of Nerium oleander (common oleander) and _________ CONCLUSION REFERENCES 128 A Fatal Case of Suicide Fruit Ingestion in Singapore by Cerbera cardiac Glycoside intoxication Y. Lee et al. Thevetia peruviana (yellow oleander) poisoning. Toxicon. 2010; 56:273–81.
34. Levine M, Nikkanen H, Pallin DJ. The effects of intravenous calcium in patients with digoxin toxicity. J Emerg Med. 2011; 40:41–6.
35. Hack JB, Woody JH, Lewis DE, Brewer K, Meggs WJ. The Effect of Calcium Chloride in Treating Hyperkalemia Due to Acute Digoxin Toxicity in a Porcine Model. Journal of Toxicology: Clinical Toxicology. 2004; 42:337–42.
36. Muller SH, Diaz JH, Kaye AD. Clinical applications of intravenous lipid emulsion therapy. J Anesth. 2015; 29:920–6.
37. Weinberg G. Lipid Rescue Resuscitation from Local Anaesthetic Cardiac Toxicity. Toxicol Rev. 2006; 25:139–45.
38. Yurtlu BS, Özbilgin Ş, Yurtlu DA, et al. Intravenous lipid emulsion prolongs survival in rats intoxicated with digoxin. Am J Emerg Med. 2016; 34:1112–6.
39. Bejarovski NG Lipid Rescue Therapy and High-Dose Insulin Euglycemic Therapy are Effective for Severe Refractory Calcium Channel Blocker Overdose: Case Report and Review of Literature. Asia Pac J Med Toxicol. 2013; 2(3): 114-116.
40. Mir SA & Rasool R Reversal Of Cardiovascular Toxicity in Severe Organophosphate Poisoning with 20% Intralipid Emulsion Therapy: Case Report and Review of Literature. Asia Pac J Med Toxicol. 2014; 3: 169-72.
41. Mowry JB, Burdmann EA, Anseeuw K, Ayoub P, Ghannoum M, Hoffman RS, et al. Extracorporeal treatment for digoxin poisoning: systematic review and recommendations from the EXTRIP Workgroup. Clin Toxicol. 2016; 54:103–14.
42. Nissenson AR, Fine RE. Handbook of Dialysis Therapy 5th ed. Elsevier, 2016;1143.
43. Wang GS, Levitan R, Wiegand TJ, Lowry J, Schult RF, Yin S, et al Extracorporeal Membrane Oxygenation (ECMO) for Severe Toxicological Exposures: Review of the Toxicology Investigators Consortium (ToxIC). J Med Toxicol. 2016; 12:95–9.
44. Kim Z, Goldfarb D, S: Continuous Renal Replacement Therapy Does Not Have a Clear Role in the Treatment of Poisoning. Nephron Clin Pract 2010;115:c1-c6. doi: 10.1159/000286343
45. Wang GS, Levitan R, Wiegand TJ, Lowry J, Schult RF, Yin S, et al. Extracorporeal Membrane Oxygenation (ECMO) for Severe Toxicological Exposures: Review of the Toxicology Investigators Consortium (ToxIC). Journal of Medical Toxicology. 2016 Mar 1;12(1):95–9. Doi: 10.1007/s13181- 015-0486-8
46. Lewis, J., Zarate, M., Tran, S Albertson T.The Recommendation and Use of Extracorporeal Membrane Oxygenation (ECMO) in Cases Reported to the California Poison Control System. J. Med. Toxicol. 15, 169–177 (2019). https://doi.org/10.1007/s13181-019-00704-3